| scholarly article | Q13442814 |
| P356 | DOI | 10.1586/EHM.09.60 |
| P953 | full work available at URL | http://www.future-drugs.com/doi/abs/10.1586/ehm.09.60 |
| http://www.tandfonline.com/doi/pdf/10.1586/ehm.09.60 | ||
| P698 | PubMed publication ID | 21082959 |
| P50 | author | Francesco Onida | Q57076605 |
| P2093 | author name string | Giorgio Lambertenghi Deliliers | |
| Claudio Annaloro | |||
| P2860 | cites work | Haematologica | Q5638209 |
| Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS) | Q22241644 | ||
| Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease | Q28239613 | ||
| Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus | Q28297489 | ||
| Capillary regeneration in scleroderma: stem cell therapy reverses phenotype? | Q33314922 | ||
| Autoimmune thrombocytopenia following autologous hematopoietic cell transplantation: review of literature and treatment options | Q33335142 | ||
| Autoimmune thrombocytopenic purpura after autologous stem cell transplantation. | Q33348608 | ||
| Haematopoietic stem cell transplantation for immune thrombopenia and other refractory autoimmune cytopenias. | Q33362076 | ||
| Autologous stem cell transplantation in autoimmune diseases | Q33377153 | ||
| Autoimmune disease after autologous hematopoietic stem cell transplantation | Q33378248 | ||
| Autologous peripheral blood stem cell transplantation in a patient with chronic autoimmune thrombocytopenia. | Q33500729 | ||
| Autologous peripheral blood stem and progenitor (CD34+) cell transplantation for systemic lupus erythematosus complicated by Evans syndrome | Q33504120 | ||
| Bone marrow transplantation for autoimmune diseases | Q33584996 | ||
| Organ-specific and systemic autoimmune diseases originate from defects in hematopoietic stem cells | Q33865273 | ||
| Autologous haematopoietic stem cell transplants for autoimmune disease--feasibility and transplant-related mortality. Autoimmune Disease and Lymphoma Working Parties of the European Group for Blood and Marrow Transplantation, the European [...] | Q33876528 | ||
| New horizons in the treatment of autoimmune diseases: immunoablation and stem cell transplantation | Q33895993 | ||
| Hematopoietic cell transplantation for Crohn's disease; is it time? | Q34017756 | ||
| Complications of autologous hematopoietic stem cell transplantation | Q34154438 | ||
| Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases | Q34208641 | ||
| High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis | Q34237823 | ||
| Regression of adjuvant-induced arthritis in rats following bone marrow transplantation | Q34326759 | ||
| Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure? | Q34503970 | ||
| Meta-analysis: mortality in Crohn's disease. | Q34578300 | ||
| High-dose immunosuppression and hematopoietic stem cell transplantation in autoimmune disease: clinical review | Q34685502 | ||
| High dose chemotherapy and autologous hematopoietic stem cell transplantation for rheumatoid arthritis: a review. | Q34744649 | ||
| High-dose immunoablative therapy with hematopoietic stem cell support in the treatment of severe autoimmune disease: current status and future direction | Q34812964 | ||
| Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study | Q34934840 | ||
| Mobilization, harvesting and selection of peripheral blood stem cells in patients with autoimmune diseases undergoing autologous hematopoietic stem cell transplantation. | Q51072274 | ||
| The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. | Q51648841 | ||
| Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease. | Q51735748 | ||
| Direct assessment of thymic reactivation after autologous stem cell transplantation. | Q52920124 | ||
| Long-term prognosis in Crohn's disease: factors that affect quality of life. | Q53261448 | ||
| The origin of increasing utilization of hematopoietic stem cell transplantation (HSCT) for severe autoimmune diseases (SAD). Introduction. | Q53443452 | ||
| Autologous hematopoietic stem cell transplantation in systemic lupus erythematosus patients with cardiac dysfunction: feasibility and reversibility of ventricular and valvular dysfunction with transplant-induced remission. | Q53555064 | ||
| Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used. | Q53587111 | ||
| Recurrence of autoimmune disease after autologous peripheral blood stem cell transplantation for multiple myeloma. | Q53587160 | ||
| Long term complete remission of severe nephrotic syndrome secondary to diffuse global (IV-G) lupus nephritis following autologous, haematopoietic peripheral stem (CD34+) cell transplantation. | Q53636289 | ||
| Autologous PBPCT in a patient with lymphoma and Sjögren's syndrome: complete remission of lymphoma without control of the autoimmune disease. | Q54128075 | ||
| Changes of matrix metalloproteinase-9 and its tissue inhibitor (TIMP-1) after autologous hematopoietic stem cell transplantation in multiple sclerosis. | Q54356211 | ||
| Pseudoautologous blood stem cell transplantation for refractory chronic graft-versus-host disease. | Q54671654 | ||
| A Three-Year Study of Brain Atrophy after Autologous Hematopoietic Stem Cell Transplantation in Rapidly Evolving Secondary Progressive Multiple Sclerosis | Q57911843 | ||
| Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis | Q57911902 | ||
| Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study | Q58416201 | ||
| Autologous stem cell transplantation for progressive multiple sclerosis: Update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database | Q59389223 | ||
| Stopping diabetes in its tracks: autologous non-myeloablative stem cell transplantation | Q60651249 | ||
| Prolonged remission state of refractory adult onset Still's disease following CD34-selected autologous peripheral blood stem cell transplantation | Q60671969 | ||
| Is there a role for mesenchymal stem cells in autoimmune diseases? | Q61657762 | ||
| Autologous Stem Cell Transplantation for Severe Autoimmune Diseases: A 10-Year Experience | Q61657765 | ||
| Renewing the T cell repertoire to arrest autoimmune aggression | Q61981581 | ||
| Autologous hematopoietic stem cell transplantation for autoimmune diseases | Q63214396 | ||
| Haematopoietic stem cell transplantation for active systemic lupus erythematosus | Q64388792 | ||
| The promise of hematopoietic stem cell transplantation for autoimmune diseases | Q35106133 | ||
| Autologous hematopoietic stem cell transplantation for Crohn's disease | Q35172136 | ||
| Experimental basis for the treatment of autoimmune diseases with autologous hematopoietic stem cell transplantation | Q35204103 | ||
| Haematopoietic stem cell transplantation for the treatment of systemic sclerosis and other autoimmune disorders | Q35547252 | ||
| Autologous stem cell transplantation in a case of treatment resistant central nervous system lupus | Q35549152 | ||
| Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease | Q35550480 | ||
| Myeloid related protein 8 and 14 secretion reflects phagocyte activation and correlates with disease activity in juvenile idiopathic arthritis treated with autologous stem cell transplantation | Q35552384 | ||
| Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry | Q35554404 | ||
| A phase I-II trial of autologous peripheral blood stem cell transplantation in the treatment of refractory autoimmune disease | Q35636989 | ||
| Haematopoietic stem cell transplantation for vasculitis including Behcet's disease and polychondritis: a retrospective analysis of patients recorded in the European Bone Marrow Transplantation and European League Against Rheumatism databases and a r | Q35638755 | ||
| High-dose immunosuppression and autologous hematopoietic stem cell rescue for severe multiple sclerosis | Q35672606 | ||
| Autologous stem cell transplantation for systemic lupus erythematosus | Q35824509 | ||
| Autologous hemopoietic stem cell transplantation in the treatment of multiple sclerosis: rationale and clinical experience | Q35840005 | ||
| Hematopoietic stem cell transplantation in multiple sclerosis: experimental evidence to rethink the procedures | Q35840009 | ||
| Stem cell transplantation for autoimmune disorders. Rheumatoid arthritis | Q35859411 | ||
| Stem cell transplantation for autoimmune disorders. Immune reconstitution | Q35859428 | ||
| Haematopoietic stem cell transplantation for autoimmune disease: limits and future potential | Q35859432 | ||
| Cell therapy for autoimmune diseases | Q35868954 | ||
| Haematopoietic stem cell transplantation for autoimmune disorders: the American perspective | Q35870515 | ||
| Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis | Q35934224 | ||
| Non-myeloablative stem cell transplantation for autoimmune diseases | Q35953258 | ||
| Autologous haematopoietic-stem-cell transplantation for multiple sclerosis | Q35994389 | ||
| Haemopoietic stem cell transplantation in autoimmune diseases: a European perspective | Q36027318 | ||
| High-dose therapy for autoimmune neurologic diseases | Q36051894 | ||
| Blood stem cells as therapy for severe lupus | Q36239643 | ||
| Hemopoietic stem cell transplantation in rheumatic diseases--an update | Q36246876 | ||
| Autologous hematopoietic stem cell transplantation for autoimmune diseases | Q36306181 | ||
| Gene therapy strategies towards immune tolerance to treat the autoimmune diseases | Q36395610 | ||
| Differential responsiveness to immunoablative therapy in refractory rheumatoid arthritis is associated with level and avidity of anti-cyclic citrullinated protein autoantibodies: a case study | Q36401901 | ||
| Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. | Q36402704 | ||
| Macrophage activation syndrome and other systemic inflammatory conditions after BMT. | Q36406434 | ||
| Adult stem cells in the treatment of autoimmune diseases | Q36508132 | ||
| Autoimmunity following haematopoietic stem-cell transplantation | Q36797795 | ||
| Reciprocal allogeneic bone marrow transplantation between NOD mice and diabetes-nonsusceptible mice associated with transfer and prevention of autoimmune diabetes | Q69511002 | ||
| Effect of human cord blood transfer on survival and disease activity in MRL-lpr/lpr mice | Q72129456 | ||
| Guillain-Barre syndrome following autologous bone marrow transplantation | Q72655127 | ||
| Reduced perforin expression in systemic juvenile idiopathic arthritis is restored by autologous stem-cell transplantation | Q73023710 | ||
| Crohn's disease complicated by relapsed extranodal Hodgkin's lymphoma: prolonged complete remission after unmanipulated PBPC autotransplant | Q73197297 | ||
| Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study | Q73208431 | ||
| Treatment-related mortality in 1000 consecutive patients receiving high-dose chemotherapy and peripheral blood progenitor cell transplantation in community cancer centers | Q73348803 | ||
| Multiple autoimmune events after autologous bone marrow transplantation | Q73348838 | ||
| Autologous marrow stem cell transplantation for severe systemic lupus erythematosus of long duration | Q73585765 | ||
| Immune thyroiditis after transplantation of allogeneic CD34+ selected peripheral blood cells | Q73909228 | ||
| Recurrent idiopathic iridocyclitis after autologous peripheral blood stem-cell transplantation followed by G-CSF administration for acute lymphoblastic leukemia | Q73932408 | ||
| Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis | Q74043339 | ||
| Autologous blood stem cell transplantation in refractory systemic lupus erythematosus with severe pulmonary impairment: a case report | Q74455226 | ||
| Autologous peripheral blood stem cell transplantation and anti-B-cell directed immunotherapy for refractory auto-immune haemolytic anaemia | Q74489848 | ||
| Cytogenetic and myelodysplastic alterations after autologous hemopoietic stem cell transplantation | Q74593014 | ||
| Impaired bone marrow hematopoietic progenitor cell function in rheumatoid arthritis patients candidated to autologous hematopoietic stem cell transplantation | Q75331826 | ||
| Bone Marrow Transplantation for Non-Malignant Disease | Q77148547 | ||
| Autoreactive antibodies following autologous peripheral blood stem cell transplantation | Q77567807 | ||
| Malignancy-associated remission of systemic lupus erythematosus maintained by autologous peripheral blood stem cell transplantation | Q77742388 | ||
| Control of severe systemic lupus erythematosus after high-dose immunusuppressive therapy and transplantation of CD34+ purified autologous stem cells from peripheral blood | Q78020643 | ||
| Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure? | Q78512358 | ||
| Hemopoietic progenitor cells and bone marrow stromal cells in patients with autoimmune hepatitis type 1 and primary biliary cirrhosis | Q79185420 | ||
| Autologous peripheral blood stem cell transplantation for severe multiple sclerosis | Q79270345 | ||
| Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells | Q79306159 | ||
| Autologous hematopoietic stem cell transplantation for progressive multiple sclerosis: report of efficacy and safety at three yr of follow up in 21 patients | Q79911192 | ||
| Reversal of autoimmune disease in lupus-prone New Zealand black/New Zealand white mice by nonmyeloablative transplantation of purified allogeneic hematopoietic stem cells | Q80160255 | ||
| Pulmonary fibrosis in systemic sclerosis: is treatment with cyclophosphamide more effective than placebo? | Q80371153 | ||
| Phenotypical and functional characteristics of in vitro expanded bone marrow mesenchymal stem cells from patients with systemic sclerosis | Q80384848 | ||
| Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis | Q80384852 | ||
| Autologous stem cell transplantation in children with severe progressive systemic or polyarticular juvenile idiopathic arthritis: long-term follow-up of a prospective clinical trial | Q80544807 | ||
| The rationale behind autologous autoimmune hematopoietic stem cell transplant conditioning regimens: concerns over the use of total-body irradiation in systemic sclerosis | Q80552104 | ||
| Long-term followup of health status in patients with severe rheumatoid arthritis after high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation | Q80955730 | ||
| Resetting the immune system in refractory Crohn's disease: is autologous hematopoietic stem cell transplantation the way forward? | Q81517849 | ||
| Antiphospholipid syndrome in patients with systemic lupus erythematosus treated by autologous hematopoietic stem cell transplantation | Q81712990 | ||
| Tolerance induction by bone marrow transplantation in a multiple sclerosis model | Q81756958 | ||
| Survival, and time to an advanced disease state or progression, of untreated patients with moderately severe multiple sclerosis in a multicenter observational database: relevance for design of a clinical trial for high dose immunosuppressive therapy | Q83184249 | ||
| Autologous stem cell transplantation for autoimmunity induces immunologic self-tolerance by reprogramming autoreactive T cells and restoring the CD4+CD25+ immune regulatory network | Q94462415 | ||
| Stem cell transplantation in multiple sclerosis: safety and ethics. | Q36873863 | ||
| Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance. | Q37008210 | ||
| Haematopoietic stem cell gene therapy to treat autoimmune disease | Q37066480 | ||
| Will hematopoietic stem cell transplantation cure human autoimmune diseases? | Q37068232 | ||
| Guillain-Barré syndrome after transplantation | Q37071692 | ||
| A novel method of bone marrow transplantation (BMT) for intractable autoimmune diseases | Q37076764 | ||
| Autologous haematopoietic stem-cell transplantation in multiple sclerosis | Q37195389 | ||
| Cellular therapy of systemic sclerosis | Q37220543 | ||
| Hematopoietic stem cell transplantation procedures | Q37311043 | ||
| Intensive immunosuppression with high dose cyclophosphamide but without stem cell rescue for severe autoimmunity: advantages and disadvantages | Q37311065 | ||
| Transplantation of autoimmune potential. I. Development of antinuclear antibodies in H-2 histocompatible recipients of bone marrow from New Zealand Black mice | Q37446632 | ||
| Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project | Q37568787 | ||
| Rationale for bone marrow transplantation in the treatment of autoimmune diseases | Q37684922 | ||
| Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus | Q38409483 | ||
| G-CSF enhances the adhesion of encephalitogenic T cells to extracellular matrix components: a possible mechanism for exacerbation of multiple sclerosis | Q40334848 | ||
| Discordant functional and inflammatory parameters in multiple sclerosis patients after autologous haematopoietic stem cell transplantation | Q40500336 | ||
| Autologous peripheral blood stem cell transplantation with in vivo T-cell depletion for life threatening refractory systemic lupus erythematosus | Q40513557 | ||
| Hematopoietic stem cell transplantation for severe Crohn's disease | Q40551797 | ||
| A phase I/II dose escalation study of intensified cyclophosphamide and autologous blood stem cell rescue in severe, active rheumatoid arthritis | Q40790584 | ||
| Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system | Q43527343 | ||
| Stem cell transplantation for autoimmune disorders. Refractory juvenile idiopathic arthritis | Q43542446 | ||
| Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. | Q43668453 | ||
| Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study | Q43765361 | ||
| Increased apoptosis of bone marrow CD34(+) cells and impaired function of bone marrow stromal cells in patients with systemic lupus erythematosus | Q43808480 | ||
| Autoimmune neutropenia following peripheral blood stem cell transplantation | Q43857211 | ||
| Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients | Q44213845 | ||
| Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. | Q44441787 | ||
| High-dose immunosuppression with autologous stem cell transplantation in severe refractory systemic lupus erythematosus. | Q44470266 | ||
| Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life | Q45152665 | ||
| High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation as a treatment option in multiple sclerosis | Q46156228 | ||
| Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. | Q46917405 | ||
| Successful treatment of rapidly progressive interstitial pneumonia with autologous peripheral blood stem cell transplantation in a patient with dermatomyositis | Q47794620 | ||
| Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis | Q48034648 | ||
| The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study. | Q48183752 | ||
| Hematopoietic stem cell transplantation in autoimmune diseases: algorithm for cardiovascular assessment | Q48261557 | ||
| Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis | Q48276129 | ||
| Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis. | Q48487021 | ||
| Autologous blood stem cell transplantation in refractory systemic lupus erythematodes with recurrent longitudinal myelitis and cerebral infarction | Q48547426 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | stem cell transplantation | Q65592366 |
| P304 | page(s) | 699-715 | |
| P577 | publication date | 2009-12-01 | |
| P1433 | published in | Expert Review of Hematology | Q15734429 |
| P1476 | title | Autologous hematopoietic stem cell transplantation in autoimmune diseases | |
| P478 | volume | 2 |
| Q33793184 | Intravenous transplantation of allogeneic bone marrow mesenchymal stem cells and its directional migration to the necrotic femoral head |
| Q35307069 | Intravenous transplantation of very small embryonic like stem cells in treatment of diabetes mellitus |
| Q37972677 | Making progress: preserving beta cells in type 1 diabetes |
| Q90116036 | Orchestrating stem cell fate: Novel tools for regenerative medicine |
| Q36997172 | Perivascular, but not parenchymal, cerebral engraftment of donor cells after non-myeloablative bone marrow transplantation |
| Q44950006 | Risk factors associated with pediatric intensive care unit admission and mortality after pediatric stem cell transplant: possible role of renal involvement |
| Q37589712 | The efficacy of targeted intraarterial delivery of concentrated autologous bone marrow containing mononuclear cells in the treatment of osteonecrosis of the femoral head: a five year follow-up study. |
| Q38012381 | Through the fog: recent clinical trials to preserve β-cell function in type 1 diabetes |
| Q56787009 | Up-regulation of fas and fasL pro-apoptotic genes expression in type 1 diabetes patients after autologous haematopoietic stem cell transplantation |
| Q50483940 | [New advances in the treatment of inflammatory bowel disease]. |
Search more.